These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 37972857)
1. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study. Milenkovikj T; Chekorova Mitreva B; Jovanovska Mishevska S; Bitoska-Mileva I; Ahmeti I; Diabetes Res Clin Pract; 2023 Dec; 206():111018. PubMed ID: 37972857 [TBL] [Abstract][Full Text] [Related]
2. PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes. Saravanan P; Bell H; Braae UC; Collins E; Deinega A; Dhatariya K; Machell A; Trent A; Strzelecka A Adv Ther; 2024 Nov; 41(11):4266-4281. PubMed ID: 39316289 [TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE). Tan X; Divino V; Amamoo J; Xie L; Coyle KB; Gamble CL; Guevarra M; Paprocki Y; King AA Clin Drug Investig; 2024 Apr; 44(4):271-284. PubMed ID: 38507188 [TBL] [Abstract][Full Text] [Related]
4. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study. Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260 [TBL] [Abstract][Full Text] [Related]
5. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Mohammedi K; Belhatem N; Berentzen TL; Catarig AM; Potier L Diabetes Obes Metab; 2023 Jul; 25(7):1855-1864. PubMed ID: 36869853 [TBL] [Abstract][Full Text] [Related]
6. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. Rajamand Ekberg N; Bodholdt U; Catarig AM; Catrina SB; Grau K; Holmberg CN; Klanger B; Knudsen ST Prim Care Diabetes; 2021 Oct; 15(5):871-878. PubMed ID: 34183269 [TBL] [Abstract][Full Text] [Related]
7. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Rudofsky G; Catarig AM; Favre L; Grau K; Häfliger S; Thomann R; Schultes B Diabetes Res Clin Pract; 2021 Aug; 178():108931. PubMed ID: 34217773 [TBL] [Abstract][Full Text] [Related]
8. Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study. Napoli R; Berra C; Catarig AM; Di Loreto C; Donatiello E; Berentzen TL; Pitocco D; Giorgino F Diabetes Obes Metab; 2023 Jun; 25(6):1658-1667. PubMed ID: 36789682 [TBL] [Abstract][Full Text] [Related]
9. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770 [TBL] [Abstract][Full Text] [Related]
11. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100 [TBL] [Abstract][Full Text] [Related]
12. Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study). Caballero Mateos I; García de Lucas MD; Doulatram-Gamgaram VK; Moreno-Moreno P; Jimenez-Millan AI; Botana-López M; Merino-Torres JF; Soto-Gónzalez A; Fernández-García JC; Morales-Portillo C Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125424 [TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378 [TBL] [Abstract][Full Text] [Related]
14. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada). Jain AB; Reichert SM; Amadid H; Braae UC; Bradley RM; Kim JW; Soo V; Yale JF Diabetes Obes Metab; 2024 May; 26(5):1799-1807. PubMed ID: 38468125 [TBL] [Abstract][Full Text] [Related]
15. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829 [TBL] [Abstract][Full Text] [Related]
16. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
17. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
18. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes. Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes. Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534 [TBL] [Abstract][Full Text] [Related]
20. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]